1. To build a transnational European network for pain-insensitivity disorders.
  2. To improve patients’ access to care, diagnostics and relevant information.
  3. To streamline genetic testing and accelerate gene discovery.
  4. To use omics and patient-specific cellular models to validate genetic variants.
  5. To understand pathomechanisms and pave the way for preclinical experimental treatment trials and clinical research.